Caplin Point Laboratories’ injectables facility completes INVIMA audit successfully
This is also an important milestone in our product strategy for our expansion into the larger Latin American market
This is also an important milestone in our product strategy for our expansion into the larger Latin American market
The company will take all necessary steps to work with USFDA towards earliest remediation of the above facility
The inspection was a cGMP Inspection and had ended with NIL observations
The expansion program includes investments in France and the U.S., adding an additional 23,000+ m² of manufacturing footprint.
The inspection was a Pre-Approval cum cGMP inspection and it covered 15 ANDAs
Launching Dexamethasone, Azacitidine, Carboprost, and Atropine for the Institutional Market
The Cephalosporin Injectables plant has a total capacity of 26.4 million vials per year while Ethiopia is having a demand for 16 million vials
Approval marks Venus Remedies’ first anti-infective marketing authorization in Indonesia and enables the country’s first generic entry for this critical antibiotic combination
The updated closure system introduces intuitive handling, innovative functionality and a premium design compatible with a wide range of syringe formats
Subscribe To Our Newsletter & Stay Updated